2. Immunology/Inflammation
  3. PD-1/PD-L1 CTLA-4
  4. Tuvonralimab

Tuvonralimab  (Synonyms: PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105)

Cat. No.: HY-P99540 Purity: 99.14%
COA

Molarity Calculator

Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab.

For research use only. We do not sell to patients.

CAS No. : 2417649-44-4

Size Price Stock Quantity
1 mg USD 350 In-stock
5 mg USD 900 In-stock
10 mg USD 1450 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tuvonralimab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Tuvonralimab contains mutations for heavy and light chain pairing (HC mutations K147D/F170C/V173C/C220G/R255K/D399R/K409E; light chain mutations S131K/Q160C/S162C/C214S), but not for the generation of a bispecific antibody. The final drug substance is a mixture of two monospecific IgGs, Iparomlimab and Tuvonralimab. The two antibodies are produced from the same cell line, with the mutations within Tuvonralimab ensuring efficient pairing of the correct chains. Iparomlimab contains no mutations[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tuvonralimab Related Antibodies
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tuvonralimab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tuvonralimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tuvonralimab2417649-44-4PSB-205 QL1706 (iparomlimab/tuvonralimab) PBS105PSB205PSB 205PBS105PBS 105PBS-105PD-1/PD-L1CTLA-4PD-1/Programmed death-ligand 1Cytotoxic T-lymphocyte-associated protein 4CD152PD-1immune checkpoint blockadeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tuvonralimab
Cat. No.:
HY-P99540
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.